About

About Morika Bio

Pioneering precision fermentation and bio-active ingredient development for global health and wellness brands.

Pioneering Precision Fermentation Since 2015

Morika Bio is a biotechnology company headquartered in Qingdao, China, specializing in precision fermentation and bio-active ingredient development. With over 30 years of enzyme engineering expertise and 110+ global patents, we deliver endotoxin-free, pharmaceutical-grade ingredients to the world's leading nutrition, wellness, and skincare brands.

Our proprietary BioSync™ platform helps eliminate endotoxin risks inherent in legacy E. coli-based fermentation and sets a higher safety standard for next-generation functional ingredients.

Mission

To make precision-bioactive ingredients accessible, safe, and sustainable for global health and wellness brands.

Vision

To be the world's most trusted supplier of endotoxin-free bio-active ingredients.

Our Journey

Innovation Milestones

A decade of pioneering precision fermentation and redefining bio-active ingredient safety standards.

2015

Company Founded

Morika Bio established in Qingdao, China, focusing on precision fermentation and bio-active ingredient research and development.

2018

R&D Platform Development

Launched proprietary AI-assisted synthetic biology platform, accelerating strain screening and product development from lab to commercial scale.

2019

HMO Breakthrough — 2'-FL & LNnT

Successfully developed 2'-FL and LNnT via precision yeast fermentation, achieving endotoxin-free production at scale.

2020

First Advanced Manufacturing Award

Recognized as one of China's 'Morning Star' Advanced Manufacturing Enterprises, highlighting our innovation in bio-manufacturing.

2021

National Dairy Innovation Center

Selected as a founding member of the National Dairy Technology Innovation Center Council, reinforcing our role in China's HMO industry.

2022

Global Expansion Begins

Presented HMO product lines at the 2022 World Advanced Manufacturing Conference. Began serving international nutrition and wellness brands.

2023

LNTr II Milestone — First FDA GRAS Globally

Achieved the world's first FDA GRAS notification for LNTr II (Lacto-N-Triose II), setting a new safety and regulatory benchmark for next-generation HMOs.

2024

Full Product Portfolio Launched

Expanded to 7 HMO variants, marine bio-peptides, and salidroside product lines. Achieved FSSC 22000, ISO 9001, Halal, GMP, and EU Novel Food certifications.

2025

50+ Countries Served

Products distributed to nutrition, wellness, and skincare brands across 50+ countries. Maintained 110+ global patents in biosynthesis.

2026

Morika Bio Global Launch

Launched the Morika Bio brand for international markets, built on the BioSync™ 3rd-Gen Precision Yeast Synthesis platform — delivering endotoxin-free, pharmaceutical-grade bio-active ingredients worldwide.